Sökresultat
Karolinska Hematology Seminar XXII
…takes place digitally and is free of charge. Karolinska Hematology Seminar is for you who are clinically active in hematology or oncology. You register by August 28, 2024 at the latest. For questions, please e-mail: [email protected] Welcome! Magnus Björkholm Karolinska University Hospital…
Enhertu godkänt i eu för patienter med HER-2 positiv metastaserande bröstcancer som haft en eller fler HER-2 inriktade behandlingar utan tillräcklig effekt
…neered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on results from the DESTINY-Breast03 Phase III trial, which were published in The New England Journal of Medicine.1 In the trial, Enhertu reduced the risk of disease progression or…
The European Code of Cancer Practice
…in Birgu, Malta. The Rights that we are championing in the European Code of Cancer Practice will empower European citizens to survive cancer and to live longer, healthier and more productive lives.”…
CHMP har rekommenderat att darolutamide får marknadsföringstillstånd inom EU
…as compared to placebo plus ADT. All other secondary endpoints, time to cytotoxic chemotherapy, and time to a symptomatic skeletal event (SSE), also demonstrated a benefit in favor of darolutamide at the time of final MFS analysis. The most frequent adverse reactions in the darolutamide plus ADT arm, that occurred with an absolute increase in frequency of ≥2% compared to placebo plus ADT, were fatigue/asthenic conditions (16% vs. 11%), pain in ex…
Lynparza rekommenderad för godkännande vid BRCA-muterad metastaserad pancreascancer i EU
…n EU by CHMP for BRCA-mutated metastatic pancreatic cancer Only PARP inhibitor to demonstrate patient benefit in a Phase III trial in this setting AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gB…